Literature DB >> 17634500

Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.

Steven E Lipshultz, Stuart R Lipsitz, Endel John Orav.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17634500     DOI： 10.1200/JCO.2007.11.8778

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  Cardiovascular disease in adult survivors of childhood cancer.

Authors:  Steven E Lipshultz; Vivian I Franco; Tracie L Miller; Steven D Colan; Stephen E Sallan
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 2.  Prevention of cardiotoxicity among survivors of childhood cancer.

Authors:  Kelley K Hutchins; Hani Siddeek; Vivian I Franco; Steven E Lipshultz
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

3.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

Review 4.  Can anthracycline therapy for pediatric malignancies be less cardiotoxic?

Authors:  Joy M Fulbright; Winston Huh; Pete Anderson; Joya Chandra
Journal:  Curr Oncol Rep       Date:  2010-11       Impact factor: 5.075

Review 5.  Treatment-related cardiotoxicity in survivors of childhood cancer.

Authors:  Steven E Lipshultz; Thomas R Cochran; Vivian I Franco; Tracie L Miller
Journal:  Nat Rev Clin Oncol       Date:  2013-10-29       Impact factor: 66.675

6.  Cardiovascular effects in childhood cancer survivors treated with anthracyclines.

Authors:  Vivian I Franco; Jacqueline M Henkel; Tracie L Miller; Steven E Lipshultz
Journal:  Cardiol Res Pract       Date:  2011-02-10       Impact factor: 1.866

7.  Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia.

Authors:  Pankit Vachhani; Sarah Shin; Jeffrey Baron; James E Thompson; Meir Wetzler; Elizabeth A Griffiths; Evelena P Ontiveros; Edward J Spangenthal; Eunice S Wang
Journal:  Leuk Res Rep       Date:  2017-04-14

Review 8.  Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment.

Authors:  Diana R Lazăr; Anca D Farcaş; Cristina Blag; Alexandra Neaga; Mihnea T Zdrenghea; Călin Căinap; Florin L Lazăr; Adrian Stef; Simona S Căinap
Journal:  Dis Markers       Date:  2021-01-06       Impact factor: 3.434

9.  Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Authors:  Robin Chung; Angshuman Maulik; Ashraf Hamarneh; Daniel Hochhauser; Derek J Hausenloy; J Malcolm Walker; Derek M Yellon
Journal:  Clin Cardiol       Date:  2016-01-25       Impact factor: 2.882
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.